Dr. Reddy's Laboratories Limited American Depositary Shares (RDY) — Analysis Summary
Dr. Reddy's Laboratories Limited American Depositary Shares (RDY) has a market cap of $9.87B with year-over-year revenue growth of +14.2%. Net margin stands at 17.6%. The stock trades at a P/E ratio of 14.6.
Key Takeaways
- Revenue changed +14.2% year-over-year
- Net margin of 17.6%
- P/E ratio of 14.6
Compared with its sector, RDY posted revenue growth of +14.2% and trades at a P/E of 14.6.
Dr. Reddy's Laboratories Limited American Depositary Shares (RDY)
UPDATED — ET · SOURCE POLYGON
Red Flags & WarningsNo Major Flags
No major credit, margin, or trend red flags were triggered from the latest filings.
Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly 40% of its generics sales, with other key markets being India (20%) and Europe (20%). Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.
Employees
27,527
Exchange
XNYS
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Annual Dividend/Share
$0.08
Dividend Yield
0.70%
Dividend History
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.